Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 235 | 38 | 193 |
| Samples | 160 | 33 | 125 |
| Peptides | 133 | 24 | 111 |
Function
DLX2 · Distal-less homeobox 2
Many vertebrate homeo box-containing genes have been identified on the basis of their sequence similarity with Drosophila developmental genes. Members of the Dlx gene family contain a homeobox that is related to that of Distal-less (Dll), a gene expressed in the head and limbs of the developing fruit fly. The Distal-less (Dlx) family of genes comprises at least 6 different members, DLX1-DLX6. The DLX proteins are postulated to play a role in forebrain and craniofacial development. This gene is located in a tail-to-tail configuration with another member of the gene family on the long arm of chromosome 2. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 123 amino-acid changes on canonical ENST00000234198 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in DLX2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DLX2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Endometrial Carcinoma | 1/42 2% | 13/612 2% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 14/1390 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 6/810 1% |
| Ovarian Carcinoma | 0/109 0% | 8/998 1% |
| Colorectal Carcinoma | 5/143 4% | 16/3239 0% |
| Gastric Carcinoma | 0/74 0% | 10/1809 1% |
| Melanoma | 3/210 1% | 8/1899 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 13/2550 1% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Other Sarcomas | 2/69 3% | 1/699 0% |
| Hepatocellular Carcinoma | 2/46 4% | 5/2210 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 3/1592 0% |
| Non-Cancerous | 1/104 1% | 1/830 0% |
| Breast Carcinoma | 0/144 0% | 7/3264 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Pancreatic Carcinoma | 2/89 2% | 1/1611 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 4/2534 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Head and Neck Carcinoma | 0/85 0% | 2/1574 0% |
| Other Solid Cancers | 0/94 0% | 2/1515 0% |
| Glioma | 0/52 0% | 1/2127 0% |
Mutation Distribution
Where DLX2 is mutated · all tissues, split by cell line vs tissue
How many mutations in DLX2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 41 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 235 mutations in DLX2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|